A subset of patients also responded to immunotherapy that targets PD-1 or CTLA-4 checkpoints (5–8), suggesting the critical role of the tumor immune microenvironment (TME) in the progression and treatment of colorectal cancer. This evidence concerns the gene CTLA4 and neoplasm.